This clinical trial is focused on studying treatments for recurrent or stage IVB cervical cancer. The study involves a medication called tisotumab vedotin, also known by its code name HuMax-TF-ADC. This medication is being tested both on its own and in combination with other treatments. The other treatments being studied in combination with tisotumab vedotin include bevacizumab, carboplatin, and pembrolizumab. Bevacizumab is a type of medication known as a recombinant humanized monoclonal antibody, carboplatin is a chemotherapy medication, and pembrolizumab is another type of monoclonal antibody.

The purpose of the study is to determine the best dose of tisotumab vedotin when used in combination with other treatments and to evaluate its effectiveness in treating cervical cancer. The study will begin with a phase called dose escalation, where different doses of the medication are tested to find the highest dose that can be given safely. After this, the study will move to a phase called dose expansion, where the focus will be on understanding how well the medication works in treating the cancer.

Participants in the study will receive the medication as a solution for infusion, which means it will be given through a vein. The study will monitor the safety of the treatments and any side effects that may occur. The trial aims to provide valuable information about the potential benefits and risks of using tisotumab vedotin, alone or in combination, for treating advanced cervical cancer.